Jeremy Bastid

Jérémy Bastid-OB is a highly skilled professional who combines drug discovery and development expertise with business management skills in the biotechnology industry. He studied Pharmacy, Oncology, Molecular and Cell Biology, Industry Management, Molecular and Cellular Biology, Oncology, and Biological and Medical Science at the renowned Université Claude Bernard Lyon 1 in France.

Bastid-OB is currently the CEO and shareholder of OREGA Biotech where he has played a crucial role in the discovery of CD39's role as a novel immune checkpoint and the development of first-in-class antibodies to neutralize its enzymatic activity. He was also the Chief Operating Officer and Program Director of the same company. He is a former R&D Director, Business Development & IP, and COO and shareholder at ORPHELIA Pharma, where he was in charge of the product portfolio strategy, clinical development, and business development.

Bastid-OB's passion for clinical projects with high unmet needs in the field of pediatric oncology and hematology, neurology, and metabolic disorders has led him to be a member and currently the R&D Director of initiative OCTALFA. He is also a former Assistant Professor at Université Claude Bernard Lyon 1, research fellow at Rhode Island Hospital, and Clerkship at Hospices Civils de Lyon.

Overall, Jérémy Bastid-OB has comprehensive knowledge and experience in drug discovery and development, especially in immuno-oncology and pediatric oncology. His expertise and skills in business development and biotech management make him a valuable asset to the industry.